 |
8 Diseases |  |
0 Trials |
|
0 Trials |  |
13 News |  |
- GSK2647544 / GSK
Trial primary completion date: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers (clinicaltrials.gov) - Jul 26, 2017
P1, N=27, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Feb 2013 --> May 2013
- GSK2647544 / GSK
Trial termination: GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers (clinicaltrials.gov) - Jun 4, 2014
P1, N=12, Terminated, Sponsor: GlaxoSmithKline
Trial primary completion date: Feb 2013 --> May 2013 Recruiting --> Terminated; Given the strength of CYP3A4 inhibition observed in Cohort 1, there is no rationale to investigate higher doses of GSK2647544 in the following two cohorts
- GSK2647544 / GSK
Enrollment change: GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers (clinicaltrials.gov) - Jun 4, 2014
P1, N=48, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Terminated; Given the strength of CYP3A4 inhibition observed in Cohort 1, there is no rationale to investigate higher doses of GSK2647544 in the following two cohorts N=70 --> 48
- GSK2647544 / GSK
Trial termination: A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier. (clinicaltrials.gov) - May 28, 2014
P1, N=4, Terminated, Sponsor: GlaxoSmithKline
N=70 --> 48 Recruiting --> Terminated; Study objectives met so study concluded earlier than planned hence we terminated the study.
- GSK2647544 / GSK
Enrollment open: A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier. (clinicaltrials.gov) - Dec 18, 2013
P1, N=8, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Terminated; Study objectives met so study concluded earlier than planned hence we terminated the study. Not yet recruiting --> Recruiting
- GSK2647544 / GSK
Enrollment open: GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers (clinicaltrials.gov) - Nov 26, 2013
P1, N=48, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | GSK2647544 / GSK
New P1 trial: GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers (clinicaltrials.gov) - Nov 5, 2013
P1, N=48, Recruiting, Sponsor: GlaxoSmithKline
- GSK2647544 / GSK
New P1 trial: A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier. (clinicaltrials.gov) - Aug 15, 2013
P1, N=8, Recruiting, Sponsor: GlaxoSmithKline
- GSK2647544 / GSK
Enrollment change: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers (clinicaltrials.gov) - Jul 10, 2013
P1, N=27, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting N=16 --> 27
- | GSK2647544 / GSK
Trial completion: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers (clinicaltrials.gov) - Jul 10, 2013
P1, N=27, Completed, Sponsor: GlaxoSmithKline
N=16 --> 27 Recruiting --> Completed
- | GSK2647544 / GSK
New P1 trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers (clinicaltrials.gov) - Oct 4, 2012
P1, N=27, Completed, Sponsor: GlaxoSmithKline